Company Overview

Aethlon Medical develops immunotherapeutic technologies to combat cancer and infectious disease. The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for 1) the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and 2) life-threatening viruses that are not addressed with approved therapies.

Aethlon Medical is currently conducting a safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during a regimen that includes pembrolizumab (Keytruda®) or nivolumab (Opdivo®) in Australia. The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial in each country is safety.

Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update
Nov 12 2026, 4:30 PM EST

Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
Sep 17 2026, 6:30 AM EDT

Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program
Aug 13 2026, 4:15 PM EDT

Stock Overview

Symbol	AEMD
Exchange	Nasdaq
Market Cap	8.05m
Last Price	$5.01
52-Week Range	$1.41 - $25.66

11/16/2026 09:00 PM EST

Aethlon Medical, Inc.

11555 Sorrento Valley Road
Suite 203
San Diego, CA 92121

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.